Updated:
CinRx Pharma
A hub and spoke biotech advancing a portfolio of high-impact medicines | CinRx Pharma is a biotech company advancing a diverse portfolio of high-impact...
CinRx Pharma
A hub and spoke biotech advancing a portfolio of high-impact medicines | CinRx Pharma is a biotech company advancing a diverse portfolio of high-impact medicines through clinical development with a unique hub-and-spoke business model. CinRx’s approach combines financing with the efficient progression of therapeutic candidates within its portfolio, each managed by CinRx’s central infrastructure and operating team. Current CinCos address areas of high unmet medical need including metabolic, gastrointestinal, and oncology.
General information
Firm type
Asset Manager
Year founded
2015
Location
Region
North America
Country
United States
City
Cincinnati
Corporate office
5375 Medpace Way, Cincinnati, OH 45227
Principals
Jon Isaacsohn
Founder & Chief Executive Officer
August Troendle
Founder & Chairman of the Board
Brian Murphy
Chief Medical Officer
Mary Bond
Chief Translational Science Officer
Sally Dressman
Chief Administrative Officer
Sector focus
Frequently asked questions
Who runs investment and asset-selection decisions at CinRx?
Founder and CEO Dr. Jon Isaacsohn leads strategic decisions, supported by Executive Director of Business Development Jason Westerheide and the Portfolio Management function headed by Mackenzie Pater. Asset evaluation draws on a systematic process that incorporates scientific, clinical, and operational screens, a logic inherited from the Medpace-trained leadership team.
How is CinRx related to Medpace?
CinRx is chaired by August Troendle, the founder and CEO of Medpace, and is headquartered at Medpace’s Cincinnati campus. Several senior CinRx executives previously held roles at Medpace, and the firm references a “strategic CRO partnership” — effectively making Medpace a dedicated clinical-operations engine for CinRx’s portfolio companies.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: